MIG - Press Review

 

2021

Alternativer Text

Börsen Zeitung, Finanzwelt, et al. -

MIG reports best year in history

Several media report about the best year in history of MIG AG
Find out more
Find out more
Find out more
Alternativer Text

Abendzeitung -

„Politics should create incentives“

Interview with Michael Motschmann, General Partner MIG AG, in „Abendzeitung“ about the future of German Biotech.
Alternativer Text

Tagesschau.de -

Advantage for mRNA-Vaccines

"tagesschau.de" has a look at the future of vaccinations against Covid-19 with quotes of Dr. Matthias Kromayer, General Partner MIG AG.
Mehr erfahren
Alternativer Text

dpa -

Biotech expects

German News Agency "dpa" reports about the Biotech Business in Germany with quotes of Michael Motschmann, General Partner MIG AG. Around 150 media published the article of dpa, among them ...
Mehr erfahren
Alternativer Text

Münchner Merkur -

How to bring buildings into a computer

„Münchner Merkur“ portrays NavVis, a MIG-portfolio company.
Alternativer Text

Manager Magazin -

Quantum Computing – it starts to be serious

A podcast of „Manager Magazin“ explains the state of the art of Quantum Computing and mentions MIG portfolio company IQM as a leading player and Michael Motschmann, General Partner MIG AG, as investor.
Find out more
Alternativer Text

Manager Magazin -

Biontech Investors put on Quantum Computing

„Manager Magazin Online“ reports about the assignment of Helmut Jeggle as Member of the Supervisory Board of IQM. The article mentions MIG Fonds and Michael Motschmann, Gneneral Partner of MIG AG, as first investor of the Finnish-German Start-up in Quantum Computing.
Find out more
Alternativer Text

Süddeutsche Zeitung -

Super Quanten

„Süddeutsche Zeitung“ reports about an innovative Quantum Computing Project of Leibnitz Rechenzentrum (LRZ) in Garching/Munich integrating IQM, a MIG portfolio company.
Find out more
Alternativer Text

VC Magazin -

„Investors got their money seven times back“

Interview with Michael Motschmann, General Partner of MIG AG, in „VC-Magazin“ about the investment in BioNTech
Find out more
Alternativer Text

Manager Magazin -

Going viral

In an article about the German Biotech Industry „Manager Magazin“ quotes Dr. Matthias Kromayer, General Partner of MIG AG.
Alternativer Text

DIE WELT -

„What in Germany is possible“ and „The Heroes of the German Vaccine Fairy Tale“

„DIE WELT“ describes the development of MIG portfolio company BioNTech und the founders. The article refers to the role of Michael Motschmann and Dr. Matthias Kromayer, General Partner of MIG AG. Additionally an interview in „DIE WELT“ with Michael Motschmann.
Find out more
Alternativer Text

Handelsblatt -

Six Start-ups are the German Hope in Quantum Computing

„Handelsblatt“ mentions IQM, a MIG portfolio company, as one of the leading German start-ups in Quantum Computing
Find out more
Alternativer Text

Börse Online -

Success with molecules

In an article about Biotech IPOs in the US, „Börse Online“ quotes Dr. Matthias Kromayer, General Partner MIG AG.
Find out more
Alternativer Text

Wirtschaftswoche -

The next enemy will be tougher

„Wirtschaftswoche“ explains the future of MIG portfolio company BioNTech with quotes of Michael Motschmann, General Partner MIG AG.
Find out more
Alternativer Text

Handelsblatt -

Serious deficits

Angela Merkel and other heads of government claim a digital pact. Dr. Jan Goetz, CEO of MIG portfolio company IQM, calls for an European approach to Quantum Computing.
Find out more
Alternativer Text

BioCentury -

The dark of COVID-19 brings promise to Germany´s biotech scene

Trade publication „BioCentury“ quotes Michael Motschmann, General Partner of MIG AG, in an article about the future of German Biotech industry.
Find out more
Alternativer Text

Tagesschau.de -

Many ideas, little money

„tagesschau.de“ reports about investments in Biotech in Germany and quotes Michael Motschmann, General Partner MIG AG.
Find out more
Alternativer Text

Finanzwelt, VC Magazin -

Next MIG Invest in Medical Technology

Several Trade Magazines report about MIGs investment in new portfolio company Creative Balloons.
Find out more
Find out more
Alternativer Text

CHEManager -

The Deals of German Biotech Investors

Trade Magazin „CHEManager“ reports about German Investors in Biotech, among them MIGs investments.
Find out more
Alternativer Text

Börsen Zeitung -

Record return for MIG because of Biontech

„Börsen Zeitung“ interviews Michael Motschmann, General Partner of MIG AG, about new developments at MIG
Alternativer Text

Finanzwelt -

MIG Fonds expand in the French Alps

„Finanzwelt“ reports about a new investment of MIG Fonds in Zadient Technologies.
Find out more
Alternativer Text

Financial Times, Reuters, Manager Magazine et al -

BioNTech Fund (MIG) pays 600m Euro dividend on back of vaccine success

International and national media among them „Financial Times“ and „Reuters“ report about the record payment of MIG Fonds of 600m Euro to investors.
Find out more
Find out more
Find out more
Find out more
Find out more
Alternativer Text

Manager Magazin -

Everything started with a dream

„Manager Magazin“ interviews Michael Motschmann, General Partner of MIG AG, and Co-Investors Thomas Strüngmann and Helmut Jeggle about their joint involvement at BioNTech SE.
Find out more
Alternativer Text

Handelsblatt -

Exosceletts reduce sick days

„Handelsblatt“ reports about the technology of GBS, a start-up producing exosceletts; MIG Fonds invested recently.
Find out more
Alternativer Text

Frankfurter Allgemeine Zeitung -

Screen Supplier to sell

„FAZ“ reports about the start of a trade sale of Cynora, a portfolio company of MIG Fonds.